{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:05:58Z","timestamp":1794603958643,"version":"4.9.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.autrev.2025.103943","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T22:39:46Z","timestamp":1760827186000},"page":"103943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Immune checkpoint inhibitor-induced inflammatory arthritis vs rheumatoid arthritis: A comparative review"],"prefix":"10.1016","volume":"25","author":[{"given":"Iliopoulos","family":"Georgios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sideridou","family":"Fani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdanos","family":"Dmitrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liew","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoussis","family":"Dimitrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103943_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103943_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105457","article-title":"Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer","volume":"90","author":"Melia","year":"2023","journal-title":"Jt Bone Spine"},{"issue":"2","key":"10.1016\/j.autrev.2025.103943_bb0015","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.rdc.2024.02.002","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: current approaches to management","volume":"50","author":"Singh","year":"2024","journal-title":"Rheum Dis Clin N Am"},{"issue":"2","key":"10.1016\/j.autrev.2025.103943_bb0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.rdc.2024.02.001","article-title":"Immune checkpoint inhibitor-induced polymyalgia rheumatica","volume":"50","author":"Liew","year":"2024","journal-title":"Rheum Dis Clin N Am"},{"issue":"3","key":"10.1016\/j.autrev.2025.103943_bb0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"10055","key":"10.1016\/j.autrev.2025.103943_bb0030","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"9","key":"10.1016\/j.autrev.2025.103943_bb0035","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/1744666X.2022.2106970","article-title":"Epidemiology of rheumatoid arthritis: genetic and environmental influences","volume":"18","author":"Venetsanopoulou","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103943_bb0040","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/imr.12832","article-title":"Immune check point inhibitor-induced inflammatory arthritis as a model of autoimmune arthritis","volume":"294","author":"Cappelli","year":"2020","journal-title":"Immunol Rev"},{"issue":"6","key":"10.1016\/j.autrev.2025.103943_bb0045","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrrheum.2016.52","article-title":"Family history of rheumatoid arthritis: an old concept with new developments","volume":"12","author":"Frisell","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103943_bb0050","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/rheumatology\/key358","article-title":"Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis","volume":"58","author":"Cappelli","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103943_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01671","article-title":"Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: a meta-analysis of randomized controlled trials","volume":"10","author":"Da","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2025.103943_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102400","article-title":"The etiology of rheumatoid arthritis","volume":"110","author":"Scherer","year":"2020","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.autrev.2025.103943_bb0065","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2025.103943_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.535784","article-title":"The antigen presenting potential of CD21low B cells","volume":"11","author":"Reincke","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103943_bb0075","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/cei\/uxac103","article-title":"A close-up on the expanding landscape of CD21\u2212\/low B cells in humans","volume":"210","author":"Gjertsson","year":"2022","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103943_bb0080","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/art.42406","article-title":"Early increase of circulating transitional B cells and autoantibodies to joint-related proteins in patients with metastatic melanoma developing checkpoint inhibitor-induced inflammatory arthritis","volume":"75","author":"Gatto","year":"2023","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"85","key":"10.1016\/j.autrev.2025.103943_bb0085","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add1591","article-title":"Clonally expanded CD38hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor-associated arthritis","volume":"8","author":"Wang","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.autrev.2025.103943_bb0090","article-title":"Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies","author":"Zhu","year":"2025","journal-title":"medRxiv [Preprint]. Serv Heal Sci"},{"key":"10.1016\/j.autrev.2025.103943_bb0095","first-page":"119","article-title":"Tertiary lymphoid organs in rheumatoid arthritis","volume":"426","author":"Rivellese","year":"2020","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.autrev.2025.103943_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1051082","article-title":"Systemic complications of rheumatoid arthritis: focus on pathogenesis and treatment","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2025.103943_bb0105","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.reuma.2023.08.001","article-title":"Neutrophils, neutrophil extracellular traps, and rheumatoid arthritis: an updated review for clinicians","volume":"19","author":"Frade-Sosa","year":"2023","journal-title":"Reumatol Clin"},{"issue":"OCT","key":"10.1016\/j.autrev.2025.103943_bb0110","article-title":"Neutrophil-derived cytokines: facts beyond expression","volume":"5","author":"Tecchio","year":"2014","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103943_bb0115","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.autrev.2017.09.012","article-title":"Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review","volume":"16","author":"Lee","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103943_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.622306","article-title":"The role of natural killer cells in autoimmune diseases","volume":"12","author":"Kucuksezer","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103943_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107392","article-title":"Fibroblast-like synoviocytes in rheumatoid arthritis: surface markers and phenotypes","volume":"93","author":"Wu","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103943_bb0130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4062\/biomolther.2020.110","article-title":"Synovial cell migration is associated with b cell activating factor expression increased by TNF\u03b1 or decreased by KR33426","volume":"28","author":"Lee","year":"2020","journal-title":"Biomol Ther (Seoul)"},{"key":"10.1016\/j.autrev.2025.103943_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102392","article-title":"An overview of autoantibodies in rheumatoid arthritis","volume":"110","author":"van Delft","year":"2020","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.autrev.2025.103943_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217624","article-title":"Immunoglobulin G structure and rheumatoid factor epitopes","volume":"14","author":"Maibom-Thomsen","year":"2019","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.autrev.2025.103943_bb0145","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/annrheumdis-2018-214967","article-title":"Anticitrullinated protein antibodies facilitate migration of synovial tissue-derived fibroblasts","volume":"78","author":"Sun","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2025.103943_bb0150","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s12016-021-08890-1","article-title":"Autoantibodies in rheumatoid arthritis: historical background and novel findings","volume":"63","author":"Sokolova","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103943_bb0155","doi-asserted-by":"crossref","first-page":"390","DOI":"10.5114\/ceji.2017.72807","article-title":"The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis","volume":"42","author":"Kurowska","year":"2017","journal-title":"Cent J Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2025.103943_bb0160","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1097\/RHU.0000000000001370","article-title":"Checkpoint inhibitor\u2013associated arthritis: a systematic review of case reports and case series","volume":"27","author":"Ghosh","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103943_bb0165","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.104367","article-title":"Opposing regulation of TNF responses by IFN-\u03b3 and a PGE2-cAMP axis that is apparent in rheumatoid and immune checkpoint inhibitor-induced arthritis human IL-1\u03b2+ macrophages","volume":"14","author":"Sokhi","year":"2025","journal-title":"Elife"},{"issue":"3","key":"10.1016\/j.autrev.2025.103943_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010758","article-title":"Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells","volume":"13","author":"Paiola","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.autrev.2025.103943_bb0175","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-025-03546-3","article-title":"Higher levels of VEGF-A and TNF\u03b1 in patients with immune checkpoint inhibitor-induced inflammatory arthritis","volume":"27","author":"Gray-Gaillard","year":"2025","journal-title":"Arthritis Res Ther"},{"issue":"Suppl. 7","key":"10.1016\/j.autrev.2025.103943_bb0180","doi-asserted-by":"crossref","first-page":"vii40","DOI":"10.1093\/rheumatology\/kez297","article-title":"Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy","volume":"58","author":"Abdel-Wahab","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.autrev.2025.103943_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093389","article-title":"Rheumatic manifestations in patients treated with immune checkpoint inhibitors","volume":"21","author":"Melissaropoulos","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"Suppl. 7","key":"10.1016\/j.autrev.2025.103943_bb0190","doi-asserted-by":"crossref","first-page":"vii68","DOI":"10.1093\/rheumatology\/kez295","article-title":"Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy","volume":"58","author":"Kostine","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103943_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152773","article-title":"Two clinical subgroups of immune checkpoint inhibitor-induced inflammatory arthritis determined by latent class analysis","volume":"74","author":"Cappelli","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2025.103943_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12081961","article-title":"Imaging findings in patients with immune checkpoint inhibitor-induced arthritis","volume":"12","author":"Ponce","year":"2022","journal-title":"Diagnostics"},{"issue":"3","key":"10.1016\/j.autrev.2025.103943_bb0205","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/BOR.0000000000000601","article-title":"Arthritis risk with immune checkpoint inhibitor therapy for cancer","volume":"31","author":"Pundole","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103943_bb0210","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2025.103943_bb0215","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/acr2.1026","article-title":"Sonographic findings in inflammatory arthritis secondary to immune checkpoint inhibition: a case series","volume":"1","author":"Albayda","year":"2019","journal-title":"ACR open Rheumatol"},{"key":"10.1016\/j.autrev.2025.103943_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152573","article-title":"Musculoskeletal ultrasound characteristics of checkpoint inhibitor-associated inflammatory arthritis","volume":"69","author":"Nasrallah","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2025.103943_bb0225","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/rheumatology\/kez361","article-title":"An MRI study of immune checkpoint inhibitor-induced musculoskeletal manifestations myofasciitis is the prominent imaging finding","volume":"59","author":"Di","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2025.103943_bb0230","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0032","article-title":"Use of magnetic resonance imaging to identify immune checkpoint inhibitor-induced inflammatory arthritis","volume":"3","author":"Subedi","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.autrev.2025.103943_bb0235","doi-asserted-by":"crossref","first-page":"e697","DOI":"10.1016\/S2665-9913(25)00061-X","article-title":"Whole-body MRI in patients with arthralgia or inflammatory arthritis after exposure to immune checkpoint inhibitors: a single-centre prospective imaging study","volume":"7","author":"Harnden","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"9746","key":"10.1016\/j.autrev.2025.103943_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.autrev.2025.103943_bb0245","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.rdc.2022.02.010","article-title":"Rheumatoid arthritis: early diagnosis and treatment","volume":"48","author":"Cush","year":"2022","journal-title":"Rheum Dis Clin N Am"},{"issue":"1","key":"10.1016\/j.autrev.2025.103943_bb0250","doi-asserted-by":"crossref","DOI":"10.7326\/AITC201901010","article-title":"Rheumatoid arthritis","volume":"170","author":"Sparks","year":"2019","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.autrev.2025.103943_bb0255","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pop.2018.02.010","article-title":"Early diagnosis and treatment of rheumatoid arthritis","volume":"45","author":"Littlejohn","year":"2018","journal-title":"Prim Care"},{"issue":"3","key":"10.1016\/j.autrev.2025.103943_bb0260","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.rdc.2013.03.007","article-title":"Imaging of rheumatoid arthritis","volume":"39","author":"Vasanth","year":"2013","journal-title":"Rheum Dis Clin N Am"},{"issue":"11","key":"10.1016\/j.autrev.2025.103943_bb0265","doi-asserted-by":"crossref","DOI":"10.1007\/s11547-019-01002-2","article-title":"Ultrasound imaging in rheumatoid arthritis","volume":"124","author":"Filippucci","year":"2019","journal-title":"Radiol Med"},{"issue":"2","key":"10.1016\/j.autrev.2025.103943_bb0270","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0038-1639474","article-title":"Magnetic resonance imaging of rheumatoid arthritis: peripheral joints and spine","volume":"22","author":"Reijnierse","year":"2018","journal-title":"Semin Musculoskelet Radiol"},{"key":"10.1016\/j.autrev.2025.103943_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102425","article-title":"Insights into the treatment of rheumatoid arthritis: A paradigm in medicine","volume":"110","author":"Smolen","year":"2020","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.autrev.2025.103943_bb0280","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.rdc.2022.03.005","article-title":"Treatment guidelines in rheumatoid arthritis","volume":"48","author":"Singh","year":"2022","journal-title":"Rheum Dis Clin N Am"},{"issue":"1","key":"10.1016\/j.autrev.2025.103943_bb0285","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11010-022-04492-3","article-title":"Rheumatoid arthritis: advances in treatment strategies","volume":"478","author":"Prasad","year":"2023","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"10.1016\/j.autrev.2025.103943_bb0290","doi-asserted-by":"crossref","DOI":"10.1186\/s13040-015-0044-6","article-title":"Mining severe drug-drug interaction adverse events using Semantic Web technologies: a case study","volume":"8","author":"Jiang","year":"2015","journal-title":"BioData Min"},{"key":"10.1016\/j.autrev.2025.103943_bb0295","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.2147\/JIR.S282600","article-title":"Monitoring and management of the patient with immune checkpoint inhibitor-induced inflammatory arthritis: current perspectives","volume":"15","author":"Chan","year":"2022","journal-title":"J Inflamm Res"},{"issue":"12","key":"10.1016\/j.autrev.2025.103943_bb0300","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1007\/s10067-020-05162-9","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: a novel clinical entity with striking similarities to seronegative rheumatoid arthritis","volume":"39","author":"Liu","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103943_bb0305","first-page":"867","article-title":"Clinical outcomes in cancer patients with immune checkpoint inhibitor-induced arthritis treated with methotrexate: a retrospective longitudinal monocentric pilot study","volume":"43","author":"Hysa","year":"2025","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103943_bb0310","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/BOR.0000000000000701","article-title":"Treatment of immune checkpoint inhibitor-induced inflammatory arthritis","volume":"32","author":"Jeurling","year":"2020","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103943_bb0315","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002612","article-title":"Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study","volume":"8","author":"De La Fuente","year":"2022","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.autrev.2025.103943_bb0320","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","article-title":"Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series","volume":"76","author":"Kim","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2025.103943_bb0325","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41584-021-00584-4","article-title":"TNF in the era of immune checkpoint inhibitors: friend or foe?","volume":"17","author":"Chen","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103943_bb0330","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/ard-2023-223885","article-title":"Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis","volume":"82","author":"Bass","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2025.103943_bb0335","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003795","article-title":"Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study","volume":"9","author":"Ladouceur","year":"2023","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.autrev.2025.103943_bb0340","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.annonc.2024.08.2340","article-title":"Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study","volume":"36","author":"Petit","year":"2025","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.autrev.2025.103943_bb0345","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","article-title":"A phase 2 trial of peresolimab for adults with rheumatoid arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103943_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115162","article-title":"Toward immune tolerance in rheumatoid arthritis: emerging immunotherapies and targets for long-term remission","volume":"162","author":"Afshari","year":"2025","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103943_bb0355","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.70002","article-title":"Chronicity of immune checkpoint inhibitor\u2013associated inflammatory arthritis after immunotherapy discontinuation: results from the canadian research group of rheumatology in immuno-oncology database","volume":"7","author":"Ladouceur","year":"2025","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103943_bb0360","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2025.103943_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2024.105795","article-title":"Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: an observational study","volume":"92","author":"Ladouceur","year":"2025","journal-title":"Jt Bone Spine"},{"issue":"12","key":"10.1016\/j.autrev.2025.103943_bb0370","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"2","key":"10.1016\/j.autrev.2025.103943_bb0375","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103943_bb0380","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12885-024-12256-z","article-title":"Immune checkpoint inhibitors in cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.autrev.2025.103943_bb0385","first-page":"64","article-title":"Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer","author":"McCarter","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103943_bb0390","first-page":"152","article-title":"Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma","author":"Tenstad","year":"2025","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103943_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1534462","article-title":"Rheumatoid arthritis associated cytokines and therapeutics modulate immune checkpoint receptor expression on T cells","volume":"16","author":"Emerson","year":"2025","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103943_bb0400","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/rheumatology\/keae343","article-title":"Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study","volume":"64","author":"Bass","year":"2025","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.autrev.2025.103943_bb0405","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/imj.16629","article-title":"Comparative study of management strategies for immune checkpoint inhibitor-induced inflammatory arthritis: rheumatologists versus oncologists","volume":"55","author":"Yoon","year":"2025","journal-title":"Intern Med J"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225002046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225002046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T13:09:24Z","timestamp":1767100164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225002046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1568997225002046"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103943","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor-induced inflammatory arthritis vs rheumatoid arthritis: A comparative review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103943"}}